Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
Hohloch, Karin, Zwick, Carsten, Ziepert, Marita, Hasenclever, Dirk, Kaiser, Ulrich, Engert, Andreas, Höffkes, Heinz-Gert, Kroschinsky, Frank, Mesters, Rolf, Feller, Andreas C, Löffler, Markus, TrümperVolume:
3
Year:
2014
Language:
english
Journal:
SpringerPlus
DOI:
10.1186/2193-1801-3-5
File:
PDF, 300 KB
english, 2014